Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1098 9064 OR L773:0094 6176 "

Sökning: L773:1098 9064 OR L773:0094 6176

  • Resultat 1-10 av 64
  • [1]234567Nästa
Sortera/gruppera träfflistan
  • Aberg, Mikael, et al. (författare)
  • Tissue Factor Noncoagulant Signaling : Mechanisms and Implications for Cell Migration and Apoptosis
  • 2015
  • Ingår i: Seminars in Thrombosis and Hemostasis. - : Georg Thieme Verlag KG. - 0094-6176 .- 1098-9064. ; 41:7, s. 691-699
  • Tidskriftsartikel (refereegranskat)abstract
    • Tissue factor (TF) is a 47-kDa transmembrane glycoprotein and the main initiator of the blood coagulation cascade. Binding to its ligand factor VIIa (FVIIa) also initiates noncoagulant signaling with broad biological implications. In this review, we discuss how TF interacts with other cell-surface proteins, which affect biological functions such as cell migration and cell survival. A vast number of publications have demonstrated the importance of TF-induced activation of protease-activated receptors, but recently published research has indicated a more complicated picture. As it has been discovered that TF interacts with integrins and receptor tyrosine kinases, novel signaling mechanisms for the TF/FVIIa complex have been presented. The knowledge of these new aspects of TF signaling may, for instance, facilitate the development of new treatment strategies for cancer and acute coronary syndromes, two examples of diseases characterized by aberrant TF expression and signaling.
  • Andersson, Nadine G., et al. (författare)
  • Intracranial Hemorrhages in Neonates : Incidence, Risk Factors and Treatment
  • 2023
  • Ingår i: Seminars in Thrombosis and Hemostasis. - : Georg Thieme Verlag KG. - 0094-6176 .- 1098-9064. ; 49:4, s. 409-415
  • Tidskriftsartikel (refereegranskat)abstract
    • Hemostasis is a dynamic process that starts in utero. Neonates, especially those who are born preterm, are at high risk of bleeding. The coagulation system evolves with age, and the decreased levels of coagulation factors along with hypo-reactive platelets are counterbalanced with increased activity of von Willebrand factor, high hematocrit and mean corpuscular volume as well as low levels of coagulation inhibitors that promote hemostasis. Neonates with congenital bleeding disorders such as hemophilia are at even higher risk of bleeding complications. This review will focus upon one of the most devastating complications associated with neonatal bleeding: intracranial hemorrhages (ICH). While etiology may be multifactorial and impacted by maternal as well as fetal risk factors, the mode of delivery certainly plays an important role in the pathogenesis of ICH. We will address prematurity and congenital bleeding disorders such as hemophilia A and B and other rare bleeding disorders as risk factors and present an updated approach for treatment and possible prevention.
  • Antovic, A, et al. (författare)
  • Impaired Fibrinolysis in the Antiphospholipid Syndrome
  • 2021
  • Ingår i: Seminars in thrombosis and hemostasis. - : Georg Thieme Verlag KG. - 1098-9064 .- 0094-6176. ; 47:055, s. 506-511
  • Tidskriftsartikel (refereegranskat)abstract
    • The pathogenesis of the antiphospholipid syndrome (APS) is complex and involves the persistent presence of antiphospholipid antibodies (aPL) in the bloodstream causing a prothrombotic condition. aPL induce excessive activation of the endothelium, monocytes, and platelets in consort with aberrations in hemostasis/clotting, fibrinolytic system, and complement activation. Impaired fibrinolysis has been found in APS patients with thrombotic as well as obstetric manifestations. Increased levels of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor, together with the presence of aPL against annexin-2, tissue-type plasminogen activator, and plasminogen contribute to the compromised fibrinolytic activity in these patients. Furthermore, unfavorably altered fibrin morphology, less amenable to fibrinolysis, has been proposed as a novel prothrombotic mechanism in APS. This review aims to summarize the present knowledge of the mechanisms involved in impaired fibrinolysis in APS patients. We also present a case from clinical practice as an illustration of fibrinolysis impairment in APS patients from a real-life setting.
  • Astermark, Jan (författare)
  • Treatment of the bleeding inhibitor patient
  • 2003
  • Ingår i: Seminars in Thrombosis and Hemostasis. - : Georg Thieme Verlag KG. - 1098-9064 .- 0094-6176. ; 29:1, s. 77-85
  • Tidskriftsartikel (refereegranskat)abstract
    • The development of inhibitory antibodies to factor (F) VIII and FIX continues to be a major challenge in the treatment of patients with hemophilia. In patients with low-responding inhibitors, it is usually possible to saturate the inhibitor with the deficient factor and to achieve hemostasis, but in patients with high-responding inhibitors, two major tasks have to be considered. One is how to treat the acute bleedings and the other is how to permanently eliminate the immune response, in other words, to induce tolerance. There are several hemostatic agents available for bleeding patients with high-responding inhibitors. Nonactivated and activated prothrombin complex concentrates (PCCs) have been used for almost 30 years, and since the beginning of the 1980s, porcine FVIII has also been used. In more recent years, recombinant FVIIa has been added to the therapeutic armamentarium and has been shown to control hemostasis in most patients. Immunoadsorption may temporarily reduce the inhibitor, enabling replacement therapy for several days. Available data on these alternative regimens will be discussed with a focus on the mechanisms of action, pharmacokinetics, safety, monitoring, and clinical experience.
  • Babiker, Adil A., et al. (författare)
  • Prothrombotic effects of prostasomes isolated from prostatic cancer cell lines and seminal plasma
  • 2007
  • Ingår i: Seminars in Thrombosis and Hemostasis. - : Georg Thieme Verlag KG. - 0094-6176 .- 1098-9064. ; 33:1, s. 80-86
  • Forskningsöversikt (refereegranskat)abstract
    • Thromboembolism is well recognized as a major complication of cancer. Many tumor cells overexpress tissue factor (TF), which activates blood coagulation in cancer patients. Inflammatory cells expressing TF are also contributors to this activation. In prostate cancer, we believe that prostasomes may also be involved in the initiation of blood coagulation. Prostasomes are submicron secretory granules derived from the prostate gland. They are surrounded by membrane and their extracellular appearance and membrane architecture are complex. Seminal prostasomes are believed to be necessary for successful fertilization and act as protectors of the spermatozoa in the lower and upper female genital tract. Cells from prostate cancer and its metastases are able to produce and export prostasomes to the extracellular environment. These prostasomes may differ quantitatively rather than qualitatively from their normal counterparts with regard to protein composition and function. A majority of human prostate cancers have been found to overexpress TF, and we have demonstrated by various methods that prostasomes derived from prostate cancer cells express considerably higher levels of TF compared with prostasomes of nonmalignant cell origin. The mechanism related to thromboembolic disease generated by prostasomes in prostatic cancer patients may be the early release of prostasomes from prostate cancer cells into the blood circulation, where they will evoke their blood-clotting effects.
  • Berntorp, Erik, et al. (författare)
  • New Approaches to Using FEIBA in the Treatment of Inhibitor Patients.
  • 2006
  • Ingår i: Seminars in Thrombosis and Hemostasis. - : Georg Thieme Verlag KG. - 1098-9064 .- 0094-6176. ; 32:Suppl 2, s. 22-27
  • Tidskriftsartikel (refereegranskat)abstract
    • Managing hemophilia becomes particularly difficult in patients with inhibitory antibodies, especially in those requiring surgery or with refractory bleeding events. Equally challenging are those patients who develop autoantibodies against factor VIII (FVIII) in the absence of a prior history of FVIII deficiency (acquired hemophilia). Physicians seeking both short- and long-term treatment strategies for bleeding events must often rely on FVIII-bypassing agents such as activated prothrombin complex concentrate (e.g., factor eight bypassing activity [FEIBA VH, Baxter BioScience, Westlake Village, CA]) or recombinant factor VIIa (rFVIIa [NovoSeven, NovoNordisk, Bagsvaerd, Denmark]). Surgical procedures in patients with inhibitors present a considerable challenge, from both a risk-benefit and a cost-benefit aspect. Hemostasis is difficult to achieve in these patients and new treatment options are being explored. Similarly challenging are refractory bleeds, the management of which is likely to benefit from a systematic treatment approach.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 64
  • [1]234567Nästa
Typ av publikation
tidskriftsartikel (59)
forskningsöversikt (5)
Typ av innehåll
refereegranskat (60)
övrigt vetenskapligt/konstnärligt (4)
Schulman, S (11)
Berntorp, Erik (9)
Sundquist, Kristina (3)
Wallen, H (3)
Blomback, M (3)
Svensson, Peter J. (3)
visa fler...
Sundquist, Jan (3)
Memon, Ashfaque A. (3)
Dahlbäck, Björn (3)
Svensson, J (2)
Bergqvist, D (2)
Palmér, Karolina (2)
Svensson, M. (1)
Majeed, A (1)
Ronquist, G. (1)
Aberg, Mikael (1)
Eriksson, Oskar (1)
Siegbahn, Agneta (1)
Ageno, W. (1)
Lindblad, B (1)
Frisell, J (1)
Nilsson Ekdahl, Kris ... (1)
Nilsson, Bo (1)
Herwald, Heiko (1)
Meijers, Joost C. M. (1)
Södergren, Anna (1)
Riva, N (1)
Bang, SM (1)
Sartori, MT (1)
Grandone, E (1)
Beyer-Westendorf, J (1)
Barillari, G (1)
Di Minno, MND (1)
Dentali, F (1)
Hedner, Ulla (1)
Bellander, BM (1)
Thelin, EP (1)
Hansson, Emma C., 19 ... (1)
Jeppsson, Anders, 19 ... (1)
Ronquist, Gunnar (1)
Zöller, Bengt (1)
Nilsson, B (1)
Ji, Jianguang (1)
Horn, A (1)
Li, Xinjun (1)
Tedgård, Ulf (1)
Islam, Md. Shahidul (1)
Bartek, J (1)
Islam, MS (1)
Karch, Helge (1)
visa färre...
Lunds universitet (30)
Karolinska Institutet (24)
Uppsala universitet (7)
Göteborgs universitet (2)
Umeå universitet (2)
Högskolan Kristianstad (1)
visa fler...
Örebro universitet (1)
Linköpings universitet (1)
Linnéuniversitetet (1)
visa färre...
Engelska (64)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (37)
Naturvetenskap (1)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy